MultivisionDx
Category: AI in Healthcare
AI-powered spatial biology diagnostics platform that creates patient-specific tumor fingerprints by analyzing tumor microenvironments using computer vision and machine learning to predict treatment responses for solid cancers. MultivisionDx was founded in 2025. The company is led by Michael Wittinger. Based in Helsinki, Finland. Team size: 5-10. Total funding raised: €1.0M. Latest round: Pre-Seed round (€1.0M, Dec 2025). Key investors include ["Antler (lead investor)","Helsinki University Funds","Kaikarhenni Oy","Finnish angel investor"].
- Founded
- 2025
- Headquarters
- Helsinki, Finland
- Team size
- 5-10
- Total funding
- €1.0M
Value proposition
Predicts cancer treatment responses more accurately than standard diagnostic criteria by generating patient-specific tumor profiles that assess aggressiveness and match patients with the most effective therapies.
Products and solutions
["Computer Vision Biomarker Discovery Platform","First-in-class Composite Biomarker for Head-and-Neck Cancer","AI-powered Decision-support Tools for Treatment Selection","Automated Spatial Biology Image Analysis System","Research Tool for Clinical Studies (market entry end 2025)"]
Unique value
Creates patient-specific 'cancer fingerprints' by integrating biological and spatial features of tumor microenvironments with subcellular precision, analyzing millions of cells to identify aggressive disease forms at early stages. Unlike other image-based tools that automate manual processes, MultivisionDx provides novel biological information about each patient's unique tumor that was previously unavailable to clinicians.
Target customer
Oncologists, cancer clinics, pathology departments, digital pathology platform companies, healthcare systems specializing in solid tumor treatment
Industries served
["Healthcare AI","Cancer Diagnostics","Precision Medicine","Spatial Biology","Digital Pathology","Oncology"]
Technology advantage
Combines computer vision-based biomarker discovery with spatial biology analysis and machine learning to analyze protein expression, cellular sizes and shapes, spatial cellular arrangements, and microenvironment composition. Technology validated in 650-patient study published in Cell journal, demonstrating superior predictive performance over existing diagnostic criteria. Scalable across various solid tumors and potentially other diseases where tissue biopsies are part of diagnostic process.
How they differentiate
Creates patient-specific 'cancer fingerprints' using spatial biology and AI to predict treatment response, with technology validated in a 650-patient study published in Cell journal showing superior performance over standard diagnostic criteria. First-in-class composite biomarker for head-and-neck cancer with pending patents on both platform technology and specific biomarkers.
Main competitors
["Nucleai","PathAI","Owkin"]
Key partnerships
["University of Helsinki (technology origin and spin-out)","University of Turku (research collaboration)","Max Planck Institute for Molecular Biomedicine, Germany (partnership)","Health Incubator Helsinki (incubator program participant since spring 2025)","Antler (lead investor)","Helsinki University Funds (investor)","Business Finland (Research to Business funding support)","Planned partnerships with digital pathology companies in Europe and US"]
Notable customers
["University of Helsinki","University of Turku","Max Planck Institute for Molecular Biomedicine"]
Major milestones
["Spun out from University of Helsinki in April 2025","Technology validated in 650-patient study published in Cell journal (Oct 2024)","Won 2025 Medix Prize for top biomedical research in Finland","Winner of Y Science 2023 Health Pitch Competition","€1M pre-seed funding round closed December 2025","Pending patents for biomarker-discovery platform and first-in-class composite biomarker for head-and-neck cancer","Participant in Health Incubator Helsinki program since spring 2025"]
Growth metrics
Successfully spun out from University of Helsinki following Research-to-Business project; technology validated in 650-patient study; winner of 2025 Medix Prize; active development for head-and-neck and colorectal cancers
Market positioning
Early-stage European healthtech spinout from University of Helsinki developing AI-powered spatial biology diagnostics for personalized cancer treatment selection, targeting research tool market entry by end 2025 and diagnostic product market 2026-2027
Geographic focus
Finland (Nordics), Europe, with planned expansion to US digital pathology partnerships
Patents and IP
Pending patents for: (1) Biomarker-discovery platform technology; (2) First-in-class composite biomarker for head-and-neck cancer
About Michael Wittinger
Extensive experience scaling high-growth companies in oncology, diagnostics, and regulated healthcare. Previously in charge of introducing oncology portfolios in Central Europe, with emphasis on the DACH region.
Official website: https://multivision.ai